IOS Press, 2004 - Health & Fitness - 64 pages
The efficacy of adjuvant chemotherapy was first demonstrated in the early 1970s. Prolonged follow-up of these trials confirms the lasting improvement in overall survival with the administration of adjuvant chemotherapy. The early meta-analysis offers the practicing physician a good sense of the broad trends in adjuvant therapy (both chemotherapy and hormonal therapy) but falls short during periods of rapid changes in available agents or approaches. This volume deals with different views on the early overview. One view highlights therapeutic advances that have not yet been incorporated. Another view places the overview in context, contrasting the consensus recommendations with actual delivery of therapy in the community. While the overview provides meaningful guidelines for the patient with an average risk early breast cancer, oncologists routinely struggle with patients at either end of the risk spectrum. In this volume, the use of neoadjuvant chemotherapy is looked at, which was initially reserved for patients with locally advanced or inflammatory disease. Adjuvant treatment decisions are based largely on the results of randomized clinical trials. But trials attempt to simplify. Consequently, virtually every trial is necessarily unrepresentative of the general population of breast cancer patients. Another point is that in real life, clinical therapy frequently requires a series of negotiations between patient and physician, especially with the explosion of the Internet, which makes it easier for patients to find (mis)information.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Management Recommendations for Adjuvant Systemic Breast Cancer Therapy
When Not to Treat Chemotherapy for Small 1 cm Breast Cancers
Rational Surveillance Programs for Early Stage Breast Cancer Patients After Primary
adju adjuvant chemotherapy adjuvant setting adjuvant therapy adjuvant treatment anthracycline benefit bone Bowel Project Breast and Bowel breast cancer patients Breast Cancer Trialists Buzdar CALGB carcinoma cardiac chemother chemotherapy for breast clinical trials cognitive dysfunction compared cyclophos cyclophosphamide disease docetaxel dose dose-dense doxorubicin Early Breast Cancer early stage breast effects epirubicin estrogen evaluated fluorouracil four cycles HER2 hormonal improved Intergroup juvant chemotherapy leukemia long-term lymph node median follow-up metastases methotrexate Natl Cancer Inst neoadjuvant chemotherapy node-negative node-positive NSABP oncologists Oncology operable breast cancer ovarian ablation overall survival overview paclitaxel patients receiving patients treated patients with stage phamide potential premature menopause premenopausal primary breast cancer Proc Am Soc randomized trial receptor relapse reported significant Soc Clin Oncol stage breast cancer surgery Surgical Adjuvant Breast surveillance symptoms tamoxifen taxanes testing tients tion toxicity trastuzumab tumor markers vant versus